助手标题  
全文文献 工具书 数字 学术定义 翻译助手 学术趋势 更多
查询帮助
意见反馈
   临床获益率 的翻译结果: 查询用时:0.558秒
图标索引 在分类学科中查询
所有学科
肿瘤学
更多类别查询

图标索引 历史查询
 

临床获益率
相关语句
  clinical benefit rate
     The clinical benefit rate was 85.2%(95%CI: 80.3% to 90% ).
     临床获益率为 85 .2 % (95 %可信区间 :80 .3%~ 90 % ) ;
短句来源
     The overall response rate (CR + PR) was 16.0%, clinical benefit rate (CR + PR + SD≥ 24 months) was 27.5%, disease control rate (CR+PR+SD) was 75.4%.
     总有效率 (CR +PR)为 16 .0 % ,临床获益率 (CR +PR +SD >6个月 )为 2 7.5 % ,疾病控制率 (CR +PR +SD)为 75 .4 %。
短句来源
     Major items were observed including objective response rate(ORR=CR+PR),clinical benefit rate(CBR=CR+PR+SD≥24 weeks),time to progress(TTP),time to failure(TTF),safety and toxicity.
     主要观察指标为:客观反应率(ORR=CR+PR,其中CR为完全缓解,PR为部分缓解)、临床获益率(CBR=CR+PR+SD≥24周,其中SD为疾病稳定)、肿瘤进展时间(TTP),肿瘤治疗失败时间(TTF)、安全性和毒副反应。
短句来源
     Overall objective response rate(CR+PR) was 36.7%. Clinical benefit rate(CR+PR+SD>6 months) was 50%. Disease control rate(CR+PR+SD) was 80%.
     总有效率(CR+PR)为36.7%,临床获益率为(CR+PR+SD>6个月)50%,疾病控制率(CR+PR+SD)为80%。
短句来源
     Results Of the 41 evaluable patients,4 achieved complete response and 14 partial remission,with a response rate and clinical benefit rate of 43.9% and 85.4%,respectively.
     结果在41例可评价疗效的患者中,4例达到完全缓解,14例部分缓解,有效率达43.9%,临床获益率85.4%。
短句来源
更多       
  clinical profit rate
     Results Clinical profit rate in the patients group treated with gemcitabine combined cisplatin was higer than it in the patients group treated with pirarubicin combined cisplatin(P<0.05),however,the overall response rates were similar in two groups(P>0.05);
     结果健择联合顺铂实验组的临床获益率明显高于吡柔比星联合顺铂对照组(P<0.05),有效率没有明显差异(P>0.05);
短句来源
     Results Forty-nine patients all completed the treatment. The overall response rate and clinical profit rate were higher in experiment group than control group(P<0.05 and P<0.01).
     结果全身静脉应用健择联合腹腔灌注顺铂结合体外射频热疗实验组的有效率和临床获益率均明显高于全身静脉应用吡柔比星联合腹腔灌注顺铂对照组(P<0.05,P<0.01);
短句来源
  clinical profit rates
     Results The overall response rates and clinical profit rates in the patients group treated with gemcitabine combined cisplatin peritoneal perfusion were higer than it in the patients group treated with pirarubicin combined cisplatin peritoneal perfusion(P<0.05) The quality of life score of experiment group was higher than it of control group(P<0.05).
     结果健择联合腹腔顺铂实验组的有效率和临床获益率明显高于吡柔比星联合腹腔灌注顺铂对照组(P<0.05); 实验组的生活质量评分明显优于对照组(P<0.05)。
短句来源
  “临床获益率”译为未确定词的双语例句
     the benefit rates were 53.3 and 0.0;
     临床获益率为53.3%、0;
短句来源
     Results: CBR of four groups were 75.7%,92.3%,90%,81.2%. There didn' t have significant difference(P=0.77).
     结果:临床获益率分别为75.7%,92.3%,90%,81.2%,无明显差异(P=0.77)。
短句来源
     group low level C_2 had highest clinical benefit ratio(72.22%), while the clinical benefit of group high level C_2 is the lowest(11.11%).
     低浓度C2组的临床获益率最高(72.22%),高浓度C2组最低(11.11%)。
短句来源
     the clinical benefit response rate(CR+PR+SD) was 84.4% in group A, compared to 62.8% in group B(P < 0.05);
     结果治疗组和对照组的有效率(CR+PR)分别为46.3%和34.9%(P>0.05),临床获益率(CR+PR+SD)分别为84.4%和62.8%(P<0.05);
短句来源
     The CBR of first-line endocrine and chemotherapy in these patients were 43.9% and 36.6%(P=0.437), whereas the CBR of second-line treatment were 47.8% and 24.2% (P=0.033), and the CBR of all treatments were 47.5% and 27.7% (P=0.001), respectively, these differences were all significant.
     而临床获益率一线治疗分别为43.9%和36.6%(P=0.437),但二线治疗为47.8%和24.2%(P=0.033),差异有显著意义,全部治疗为47.5%和27.7%(P=0.001)有非常显著意义;
短句来源
更多       
查询“临床获益率”译词为用户自定义的双语例句

    我想查看译文中含有:的双语例句
例句
为了更好的帮助您理解掌握查询词或其译词在地道英语中的实际用法,我们为您准备了出自英文原文的大量英语例句,供您参考。
  clinical benefit rate
Of 47 patients eligible for response (25 idoxifene, 22 tamoxifen), two partial responses and two disease stabilizations (SD) for >amp;gt;6?months were seen with idoxifene (overall clinical benefit rate 16%, 95% CI 4.5-36.1%).
      
In contrast, no objective responses were seen with the increased 40?mg/day dose of tamoxifen, although two patients had SD for 7 and 14?months (clinical benefit rate 9%, 95% CI 1.1-29.2%).
      
Conclusion: GEM in combination with celecoxib showed low toxicity, good clinical benefit rate and good disease control.
      
Two patients experienced partial responses and 118 experienced stable disease lasting ≥6 months, resulting in an overall clinical benefit rate of 29.9%.
      
The clinical benefit rate was 51.5% (95% CI: 33.5-69.2%).
      
更多          


ObjectiveTo compare the efficacy of endocrine therapy with chemotherapy for bone metastasis of breast cancer. MethodsA total of 138 breast cancer patients with bone metastasis, but without visceral metastasis as retrospectively reviewed. ResultsThe response rates of endocrine therapy and chemotherapy as the first-line therapy were 35.4% and 31.7% ( P =0.687), and the total response rates were 27.1% and 25.0% ( P =0.690). The clinical benefit rates of endocrine therapy and chemotherapy as first-line were 43.9%...

ObjectiveTo compare the efficacy of endocrine therapy with chemotherapy for bone metastasis of breast cancer. MethodsA total of 138 breast cancer patients with bone metastasis, but without visceral metastasis as retrospectively reviewed. ResultsThe response rates of endocrine therapy and chemotherapy as the first-line therapy were 35.4% and 31.7% ( P =0.687), and the total response rates were 27.1% and 25.0% ( P =0.690). The clinical benefit rates of endocrine therapy and chemotherapy as first-line were 43.9% and 36.6% ( P =0.437), as second-line were 47.8% and 24.2% ( P =0.033), in total treatments were 47.5% and 27.7% ( P =0.001). The median interval to treatment failure (TTF) was 5 months and 2 months ( P <0.001) , and that to progression (TTP) was 5 and 2.5 months ( P <0.001) in endocrine therapy and chemotherapy group, respectively. ConclusionEndocrine therapy is superior to chemotherapy for bone metastasis of breast cancer.

目的 对比分析内分泌治疗与化疗对乳腺癌骨转移的疗效。方法 对 138例无内脏转移的乳腺癌骨转移患者 ,行 2 89例次单独内分泌治疗或化疗。结果 内分泌治疗与化疗的一线治疗有效率分别为 35 .4 %和 31.7% ,差异无显著性 (χ2 =0 .16 3,P =0 .6 87) ;全部治疗有效率分别为 2 7.1%和 2 5 .0 % ,差异无显著性 (χ2 =0 .15 9,P =0 .6 90 ) ;临床获益率分别为 4 3.9%和 36 .6 % ,差异无显著性(χ2 =0 .6 0 3,P =0 .4 37)。但内分泌治疗与化疗的二线治疗临床获益率分别为 4 7.8%和 2 4 .2 % ,全部治疗为 4 7.5 %和 2 7.7% ,差异均有显著性 (χ2 =4 .5 37,P =0 .0 33;χ2 =11.2 0 1,P =0 .0 0 1)。内分泌治疗和化疗患者的中位治疗失败时间 (TTF)为 5个月和 2个月 ,中位病变进展时间 (TTP)为 5个月和 2 .5个月 ,差异均有非常显著性 (P均 <0 .0 0 1)。结论 单独内分泌治疗和化疗均为乳腺癌骨转移的有效...

目的 对比分析内分泌治疗与化疗对乳腺癌骨转移的疗效。方法 对 138例无内脏转移的乳腺癌骨转移患者 ,行 2 89例次单独内分泌治疗或化疗。结果 内分泌治疗与化疗的一线治疗有效率分别为 35 .4 %和 31.7% ,差异无显著性 (χ2 =0 .16 3,P =0 .6 87) ;全部治疗有效率分别为 2 7.1%和 2 5 .0 % ,差异无显著性 (χ2 =0 .15 9,P =0 .6 90 ) ;临床获益率分别为 4 3.9%和 36 .6 % ,差异无显著性(χ2 =0 .6 0 3,P =0 .4 37)。但内分泌治疗与化疗的二线治疗临床获益率分别为 4 7.8%和 2 4 .2 % ,全部治疗为 4 7.5 %和 2 7.7% ,差异均有显著性 (χ2 =4 .5 37,P =0 .0 33;χ2 =11.2 0 1,P =0 .0 0 1)。内分泌治疗和化疗患者的中位治疗失败时间 (TTF)为 5个月和 2个月 ,中位病变进展时间 (TTP)为 5个月和 2 .5个月 ,差异均有非常显著性 (P均 <0 .0 0 1)。结论 单独内分泌治疗和化疗均为乳腺癌骨转移的有效治疗手段 ,其中内分泌治疗优于化疗。

Objective: To evaluate the efficacy and adverse effects of letrozole for postmenopausal patients with advanced breast cancer. Methods: Sixty- three patients with advanced breast cancer received 2.5 mg/d letrozole as a single agent. Results: All patients were evaluable for adverse effects. Among these 62 patients who were evaluable for efficacy,there was no complete response, 9 (14.5 %) partial response, 30(48.4 %) stable disease, 23(37.1 %) progressive disease,and 19(30.6 %) clinical benefit (CR+PR+SD≥6months)....

Objective: To evaluate the efficacy and adverse effects of letrozole for postmenopausal patients with advanced breast cancer. Methods: Sixty- three patients with advanced breast cancer received 2.5 mg/d letrozole as a single agent. Results: All patients were evaluable for adverse effects. Among these 62 patients who were evaluable for efficacy,there was no complete response, 9 (14.5 %) partial response, 30(48.4 %) stable disease, 23(37.1 %) progressive disease,and 19(30.6 %) clinical benefit (CR+PR+SD≥6months). The response rate and clinical benefit was 44.4 %and 66.7 % in first- line treatment, 10.5 % and 36.8 % in second- line treatment, 8.8 % and 26.5 % in more than second- line treatment. The response rate of bone,soft tissue and visceral metastasis was13.3 %,12.8 % and 11.9 %, respectively.One patient stop treatment due to allergic reaction. Conclusion: Letrozole is a well tolerated agent with reasonable efficacy but low toxicity for postmenopausal patients with advanced breast cancer.

目的:观察来曲唑(Letrozole)治疗晚期乳腺癌的疗效及不良反应。方法:63例晚期乳腺癌患者给予来曲唑(进口或国产)2.5 mg口服,每日1次。结果:63例患者中,可评价疗效者62例,可评价不良反应者63例。完全缓解(CR)0例;部分缓解(PR)9例,占14.5 %;稳定(SD)30例,占48.4 %,其中SD≥6个月10例,占16.1 %;临床获益(CR+PR+SD≥6个月)19例,占30.6 %;病情进展(PD)23例,占37.1 %。一线治疗9例,有效率44.4 %,临床获益率66.7 %。二线治疗19例,有效率10.5 %,临床获益率36.8 %。三线及以上治疗34例,有效率8.8 %,临床获益率26.5 %。骨、软组织和内脏转移有效率依次为13.3 %、12.8 %和11.9 %。治疗中1例因变态反应停药,其余无严重不良反应。结论:来曲唑治疗晚期乳腺癌有一定疗效,药物不良反应轻,患者易于耐受。

Objective To evaluate the efficacy and adverse reactions of Xeloda in the treatment of recurrent and metastatic breast cancer. Methods This clinical study was designed to treat 69 patients with recurrent and metastatic breast cancer with Xeloda, 2500 mg/m 2/d, twice daily for 2 weeks followed by a 1 week rest period, repeated every 3 weeks. Results Sixty nine patients received Xeloda for more than 1 cycle. The overall response rate (CR + PR) was 16.0%, clinical benefit rate (CR + PR + SD≥ 24 months) was...

Objective To evaluate the efficacy and adverse reactions of Xeloda in the treatment of recurrent and metastatic breast cancer. Methods This clinical study was designed to treat 69 patients with recurrent and metastatic breast cancer with Xeloda, 2500 mg/m 2/d, twice daily for 2 weeks followed by a 1 week rest period, repeated every 3 weeks. Results Sixty nine patients received Xeloda for more than 1 cycle. The overall response rate (CR + PR) was 16.0%, clinical benefit rate (CR + PR + SD≥ 24 months) was 27.5%, disease control rate (CR+PR+SD) was 75.4%. The median time to failure (TTF) was 3 months (range: 0.7 11months). The median time to progression (TTP) was 2 months (range: 0.7 11months). The median duration of response (CR + PR) was 6 months (range: 4 11months). The most common treatment related adverse events were hand foot syndrome (HFS) that occurred in 60.8% (42/69) patients mostly as grade Ⅰ Ⅱ. Fifty five percent (22/40) of patients who had received high dose preventive Vit B6 developed HFS without grade Ⅲ; while 69% (20/29) of patients who had not received such treatment did develop HFS including 2 patients with grade Ⅲ. However, there was not significant difference between the two groups. Conclusion Xeloda is an effective and well tolerated treatment in patients with recurrent and metastatic breast cancer. The symptoms of HFS may be relieved by high dose Vit B6 as prevention.

目的 观察单药希罗达治疗复发转移性乳腺癌的疗效和不良反应。方法 希罗达单药治疗 6 9例复发转移性乳腺癌。希罗达用药每天 2 5 0 0mg/m2 ,早晚两次 ,餐后服用。连续服用 2周 ,休息 1周 ,为 1个周期。结果  6 9例均治疗 1周期以上。总有效率 (CR +PR)为 16 .0 % ,临床获益率 (CR +PR +SD >6个月 )为 2 7.5 % ,疾病控制率 (CR +PR +SD)为 75 .4 %。中位治疗失败时间为 3(0 .7~ 11)个月 ,中位疾病进展时间为 2 (0 .7~ 11)个月。CR和PR患者的中位缓解时间为 6 (4~ 11)个月。最常见的不良反应是手足综合征 (HFS) ,发生率为 6 0 .9% (42 /6 9) ,程度主要为Ⅰ~Ⅱ度。应用大剂量维生素B6进行预防的患者 ,HFS发生率为 5 5 .0 % (2 2 /40 ) ,无Ⅲ度HFS ;而未应用者 ,HFS发生率为 6 9.0 %(2 0 /2 9) ,有 2例为Ⅲ度HFS ;但用与未用维生素B6者 ,HFS发生率差异未见有显著性 (P =0 .2 4 1)。结论 单药希罗达对复发转移性...

目的 观察单药希罗达治疗复发转移性乳腺癌的疗效和不良反应。方法 希罗达单药治疗 6 9例复发转移性乳腺癌。希罗达用药每天 2 5 0 0mg/m2 ,早晚两次 ,餐后服用。连续服用 2周 ,休息 1周 ,为 1个周期。结果  6 9例均治疗 1周期以上。总有效率 (CR +PR)为 16 .0 % ,临床获益率 (CR +PR +SD >6个月 )为 2 7.5 % ,疾病控制率 (CR +PR +SD)为 75 .4 %。中位治疗失败时间为 3(0 .7~ 11)个月 ,中位疾病进展时间为 2 (0 .7~ 11)个月。CR和PR患者的中位缓解时间为 6 (4~ 11)个月。最常见的不良反应是手足综合征 (HFS) ,发生率为 6 0 .9% (42 /6 9) ,程度主要为Ⅰ~Ⅱ度。应用大剂量维生素B6进行预防的患者 ,HFS发生率为 5 5 .0 % (2 2 /40 ) ,无Ⅲ度HFS ;而未应用者 ,HFS发生率为 6 9.0 %(2 0 /2 9) ,有 2例为Ⅲ度HFS ;但用与未用维生素B6者 ,HFS发生率差异未见有显著性 (P =0 .2 4 1)。结论 单药希罗达对复发转移性乳腺癌疗效确切 ,患者不良反应可耐受。应用大剂量维生素B6进行预防 ,可能减轻HFS的症状 ,提高患者对希罗达的耐受性

 
<< 更多相关文摘    
图标索引 相关查询

 


 
CNKI小工具
在英文学术搜索中查有关临床获益率的内容
在知识搜索中查有关临床获益率的内容
在数字搜索中查有关临床获益率的内容
在概念知识元中查有关临床获益率的内容
在学术趋势中查有关临床获益率的内容
 
 

CNKI主页设CNKI翻译助手为主页 | 收藏CNKI翻译助手 | 广告服务 | 英文学术搜索
版权图标  2008 CNKI-中国知网
京ICP证040431号 互联网出版许可证 新出网证(京)字008号
北京市公安局海淀分局 备案号:110 1081725
版权图标 2008中国知网(cnki) 中国学术期刊(光盘版)电子杂志社